oa Central African Journal of Medicine - Field trials with 3-Chloro-9-(4-diethylamino-1-methylbutylamino) acridine, 10-oxide dihydrochloride (CI-423) as an antimalarial compound

Volume 9, Issue 12
  • ISSN : 0008-9176



The new acridine drug CI�423 was compared with Amodiaquine in Southern Rhodesia for treatment of malaria in a semi-immune population. The drug was given in two dosage schedules; the first was a single dose of 600 mg. modiaquine, or 600 mg. of CI�423 to adults, with proportionately smaller doses for children. In the second series patients received a 50 percent dose of Amodiaquine or a 33 percent dose of CI-423. At the end of 21 days there was no significant difference between the drugs at the full dosage level, but Amodiaquine was significantly better at the lower levels. It seems probable that this difference was due to the inequality of dosages. No difference in effect on gametocytes could be found between the two drugs. No toxic effects or intolerance were noted. The new drug, CI-423, appears to hold promise as an antimalarial, particularly in single dose therapy, since its efficacy at similar dosage is comparable with Amodiaquine.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error